X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The agreement aims to develop and commercialize AOB's topical biologic B244, currently preparing for global Phase 3 clinical trials, a therapeutic treatment for dermatological indications including Atopic Dermatitis, for both appearance and pruritus (itch).
Lead Product(s): B244
Therapeutic Area: Dermatology Product Name: B244
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Maruho
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 05, 2024
Details:
B244 platform is a patented, proprietary, topical formulation. Once deployed, B244 produces nitric oxide, a signaling molecule known to regulate inflammation and vasodilation. It has shown clinical significance for atopic dermatitis and associated pruritus and acne vulgaris.
Lead Product(s): B244
Therapeutic Area: Dermatology Product Name: B244
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 06, 2023
Details:
Company’s lead product candidate, B244, a live topical biotherapeutic, subject Phase 2b trial for Treatment of Pruritus associated with Atopic Dermatitis successfully completes its recruitment goal.
Lead Product(s): B244
Therapeutic Area: Dermatology Product Name: B244
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 16, 2021
Details:
A total of 30 subjects used a cream containing metabolically inactive AOB twice a day for 2 weeks. Continuing the historically strong safety profile of applied AOB, the cream formulation was well-tolerated by the subjects.
Lead Product(s): Ammonia Oxidizing Bacteria
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 17, 2021
Details:
The adult trial was a double blind, placebo controlled, multicenter, Phase 2a study of B244, a first-in-class, topical formulation of beneficial ammonia oxidizing bacteria, delivered as a topical spray twice daily for 28 days.
Lead Product(s): B244
Therapeutic Area: Dermatology Product Name: B244
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 30, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
